Condition

Colorectal Neoplasms

ClinicalTrials.gov condition label

How to interpret these research links

Connected source records

This is the original ClinicalTrials.gov condition label, found in 88 distinct published trials. It is kept separate from a MONDO disease identifier until a specific normalization is supported. Related interventions are co-recorded in studies; they are not medical recommendations.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Clinical trials88
Recruiting20
Common interventions25
Lead sponsors shown15
Advertisement

Clinical trials

60 shown
A First-in-Human Trial of BLU-924 (SAR449336) in Advanced Solid Tumors Harboring KRAS MutationsNCT07629960 · 2026-06-04
RECRUITING
DETERMINE Trial Treatment Arm 07: Dabrafenib in Combination With Trametinib in Adult, Paediatric and Teenage/Young Adult Patients With BRAF V600 Mutation-Positive Cancers.NCT07440290 · 2026-04-01
RECRUITING
A Study of LY4337713 in Participants With FAP-Positive Solid TumorsNCT07213791 · 2025-10-22
RECRUITING
DPYD Pharmacogenomics and Fluoropyrimidine (FP) Dose-AdjustmentNCT07158164 · 2025-08-27
RECRUITING
A Study of LY4257496 in Participants With Cancer (OMNIRAY)NCT07114601 · 2025-08-06
RECRUITING
Methylation Profile Test (Methylscape) in Body Fluids for Multi-Cancer Detection and Monitoring in ColombiaNCT07741435 · 2025-06-05
RECRUITING
A Study of DM002 in Patients With Advanced Solid TumorsNCT06751329 · 2025-02-17
RECRUITING
Diagnosis of Multiple Cancer and Monitoring of Minimal Residual Tumors After Treatment Using Blood and High-Sensitivity Genetic Analysis TechniquesNCT07035587 · 2024-08-21
RECRUITING
A Phase I/II Trial of UCB4594 in Participants With Advanced CancerNCT06380816 · 2024-07-09
RECRUITING
A Study of Sofe-M in Participants With Selected Advanced Solid TumorsNCT06400472 · 2024-05-20
RECRUITING
A Study of SGN-CEACAM5C in Adults With Advanced Solid TumorsNCT06131840 · 2023-11-20
RECRUITING
HTL0039732 in Participants With Advanced Solid TumoursNCT05944237 · 2023-08-02
RECRUITING
DETERMINE Trial Treatment Arm 04: Trastuzumab in Combination With Pertuzumab in Adult, Paediatric and Teenage/Young Adult Patients With Cancers With HER2 Amplification or Activating MutationsNCT05786716 · 2023-03-07
RECRUITING
DETERMINE Trial Treatment Arm 05: Vemurafenib in Combination With Cobimetinib in Adult Patients With BRAF Positive Cancers.NCT05768178 · 2023-03-01
RECRUITING
PRE-ISPY Phase I/II Oncology Platform ProgramNCT05868226 · 2023-02-15
RECRUITING
PDS01ADC in Combination With Hepatic Artery Infusion Pump (HAIP) and Systemic Therapy for Subjects With Metastatic Colorectal Cancer, Intrahepatic Cholangiocarcinoma, or Metastatic Adrenocortical CarcinomaNCT05286814 · 2022-10-24
RECRUITING
Metarrestin (ML-246) in Subjects With Metastatic Solid TumorsNCT04222413 · 2020-10-27
RECRUITING
Personalized Patient Derived Xenograft (pPDX) Modeling to Test Drug Response in Matching HostNCT02732860 · 2015-12-01
RECRUITING
Establishment of a Tumor Bank for Blood SamplesNCT01763125 · 2003-11-01
RECRUITING
Establishment of a Tumor Bank for Tissue SamplesNCT01789229 · 2003-09-01
RECRUITING
Increasing Breast and Colorectal Cancer Screening in the CommunityNCT07748377 · 2026-10-01
NOT_YET_RECRUITING
A Preregistered Multi-Cohort Evaluation of the FATHOM AI System for Molecular Testing Prioritization to Support Clinical Trial EnrollmentNCT07814872 · 2026-09-01
NOT_YET_RECRUITING
Exploratory Study on the Efficacy and Safety of Trastuzumab Rezetecan in the Treatment of HER2-Expressiong Advanced Solid TumorNCT07631884 · 2026-06-15
NOT_YET_RECRUITING
Nudging Preventive Screening Via Message Framing and BundlingNCT07644910 · 2026-06-08
NOT_YET_RECRUITING
A Phase II Study of GV20-0251 in Combination With Anti-PD-1 Monoclonal Antibodies in Patients With Unresectable, Locally Advanced, or Metastatic Solid Tumors.NCT07623642 · 2026-06-02
NOT_YET_RECRUITING
A Study to Learn About the Study Medicine PF-07985045 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Change in a Gene.NCT06704724 · 2024-12-10
TERMINATED
A Study of SGN-MesoC2 in Advanced Solid TumorsNCT06466187 · 2024-08-02
TERMINATED
A Study to Learn About the Study Medicine PF-07934040 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Genetic Mutation.NCT06447662 · 2024-06-27
ACTIVE_NOT_RECRUITING
Impact on Quality of Life and Health of the CONTINUUM+ CONNECT Remote Monitoring SolutionNCT06379880 · 2024-04-25
COMPLETED
A Study of PF-08046052/SGN-EGFRd2 in Advanced Solid TumorsNCT05983133 · 2023-11-14
TERMINATED
Regorafenib With Tislelizumab in Patients With Selected Mismatch Repair-Proficient/Microsatellite Stable CancersNCT05582031 · 2023-04-30
WITHDRAWN
A Study to Evaluate the Safety and Efficacy of A2B530, a Logic-gated CAR T, in Participants With Solid Tumors That Express CEA and Have Lost HLA-A*02 ExpressionNCT05736731 · 2023-04-28
ACTIVE_NOT_RECRUITING
Combination Immunotherapy in Colorectal CancerNCT05571293 · 2023-03-17
ACTIVE_NOT_RECRUITING
A Study of PF-08046049/SGN-BB228 in Advanced Melanoma and Other Solid TumorsNCT05571839 · 2023-01-03
TERMINATED
First in Human Study of AZD9592 in Solid TumorsNCT05647122 · 2022-12-21
ACTIVE_NOT_RECRUITING
Platform Study of JDQ443 in Combinations in Patients With Advanced Solid Tumors Harboring the KRAS G12C MutationNCT05358249 · 2022-10-24
ACTIVE_NOT_RECRUITING
Intravenous and Intraperitoneal Paclitaxel and Oral Nilotinib for Peritoneal CarcinomatosisNCT05185947 · 2022-10-13
COMPLETED
A Phase 1/2 Trial of TC-510 In Patients With Advanced Mesothelin-Expressing CancerNCT05451849 · 2022-06-21
TERMINATED
Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Chinese Participants With Stage IV Colorectal Cancer (MK-3475-C66)NCT05239741 · 2022-04-02
ACTIVE_NOT_RECRUITING
Safety, Tolerability, and Anti-Tumor Activity of AFM24 in Combination With SNK01 in Subjects With Advanced/Metastatic EGFR-Expressing CancersNCT05099549 · 2021-11-03
TERMINATED
Three Birds With One StoneNCT05022511 · 2021-09-01
COMPLETED
Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C)NCT04956640 · 2021-07-19
ACTIVE_NOT_RECRUITING
Evaluation of a Cosmetic Product to Preserve Skin Conditions When Using Anti-EGFR Cancer TherapiesNCT04878692 · 2021-06-01
UNKNOWN
A Home-Based Approach Study to Evaluate the Efficacy and Safety of Alectinib in Locally-Advanced or Metastatic ALK-Positive Solid TumorsNCT04644315 · 2021-05-24
TERMINATED
Study of Lenvatinib (MK-7902/E7080) in Combination With Pembrolizumab (MK-3475) Versus Standard of Care in Participants With Metastatic Colorectal Cancer (MK-7902-017/E7080-G000-325/LEAP-017)NCT04776148 · 2021-03-29
COMPLETED
A Study of SGN-STNV in Advanced Solid TumorsNCT04665921 · 2021-01-18
TERMINATED
Assessing Effectiveness and Implementation of an EHR Tool to Assess Heart Health Among SurvivorsNCT03935282 · 2020-10-01
COMPLETED
A Study of mRNA-5671/V941 as Monotherapy and in Combination With Pembrolizumab (V941-001)NCT03948763 · 2019-06-26
TERMINATED
Predictive Value of Innovative Prognostic Markers (Gut Microbiota, Sarcopenia, Metabolic Syndrome and Obesity) on Surgical and Oncologic Results in the Management of Sporadic Colorectal Adenocarcinoma.NCT03843905 · 2018-11-15
UNKNOWN
Ultrasound-enhanced Delivery of Chemotherapy to Patients With Liver Metastasis From Breast- and Colorectal CancerNCT03477019 · 2018-11-12
COMPLETED
PF-06952229 Treatment in Adult Patients With Advanced Solid TumorsNCT03685591 · 2018-10-04
TERMINATED
Safety and Efficacy of Vicriviroc (MK-7690) in Combination With Pembrolizumab (MK-3475) in Participants With Advanced/Metastatic Microsatellite Stable (MSS) Colorectal Cancer (CRC) (MK-7690-046)NCT03631407 · 2018-09-24
COMPLETED
Study of MK-1697 in Participants With Advanced Solid Tumors (MK-1697-001)NCT03515824 · 2018-08-13
TERMINATED
Efficacy and Safety Study of Tisotumab Vedotin for Patients With Solid TumorsNCT03485209 · 2018-06-25
ACTIVE_NOT_RECRUITING
Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Participants With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid TumorsNCT03037385 · 2017-03-17
COMPLETED
A Safety Study of SGN-2FF for Patients With Advanced Solid TumorsNCT02952989 · 2017-02-23
TERMINATED
An Intervention Programme to Reduce Cognitive Impairment Due to CancerNCT02581709 · 2016-05-01
TERMINATED
Determinants of Quality Of Life in AGEd Cancer PatientsNCT02672657 · 2016-02-01
UNKNOWN
Preoperative High Intensity Interval Training: The PHIIT TrialNCT02674815 · 2016-02-01
COMPLETED
Limiting Chemotherapy Side Effects by Using MoxaNCT02781155 · 2016-02-01
UNKNOWN

Common interventions

pembrolizumabDRUG5BevacizumabDRUG3carboplatinDRUG3cisplatinDRUG3LeucovorinDRUG3PembrolizumabBIOLOGICAL35-Fluorouracil (5-FU)DRUG2BevacizumabCOMBINATION_PRODUCT2CarboplatinCOMBINATION_PRODUCT2CetuximabBIOLOGICAL2CetuximabCOMBINATION_PRODUCT2CetuximabDRUG2CisplatinCOMBINATION_PRODUCT2FluorouracilCOMBINATION_PRODUCT2GemcitabineCOMBINATION_PRODUCT2LeucovorinCOMBINATION_PRODUCT2Nab-paclitaxelCOMBINATION_PRODUCT2OxaliplatinCOMBINATION_PRODUCT2OxaliplatinDRUG2PaclitaxelCOMBINATION_PRODUCT2PembrolizumabCOMBINATION_PRODUCT2PemetrexedDRUG2pemetrexedCOMBINATION_PRODUCT2SasanlimabCOMBINATION_PRODUCT2trametinibDRUG2

Trial status mix

COMPLETED30
RECRUITING20
TERMINATED16
ACTIVE_NOT_RECRUITING9
UNKNOWN7
NOT_YET_RECRUITING5
WITHDRAWN1

Phase mix

PHASE138
PHASE238
NA13
PHASE37
PHASE41
Advertisement

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.